Russia’s cancer vaccine could receive approval by August, allowing treatment to begin, the head of the Gamaleya Research Institute has said Read...
Vous n'êtes pas connecté
A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology is expected to receive regulatory approval by August, potentially allowing treatments to commence as early as September, according to the institute’s director, Alexander Gintsburg. This breakthrough marks a significant milestone in the global fight against cancer, leveraging advanced mRNA technology […]
Russia’s cancer vaccine could receive approval by August, allowing treatment to begin, the head of the Gamaleya Research Institute has said Read...
Small deviations in the structure of the monkey flower virus can lead to mass transmission of the virus through droplets in the air. This was stated...
By Rafiq Vayani KARACHI: easypaisa has achieved a groundbreaking milestone by becoming Pakistan’s first Digital Retail Bank to receive commercial...
THURSDAY, Feb. 6, 2025 -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful,...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
World Cancer Day on February 4 aims to raise awareness and combat cancer globally. The 2025 theme, 'United by Unique,' highlights a people-centered...
Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the...
Multiple Institutions Give AIM a "Buy" Rating HONG KONG SAR - Media OutReach Newswire - 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading...
Rift Valley Fever Vaccine : Hope as South African Company Joins Effort By Gift Briton Global efforts for a Rift Valley fever (RVF) vaccine accelerate...
THURSDAY, Feb. 6, 2025 -- Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell...